[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D017311:Amlodipine / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001262:Atenolol / Q000008:administration & dosage; D000069059:Atorvastatin; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control; D017292:Doxazosin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000008:administration & dosage; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D020913:Perindopril / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage*; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D006538:Heptanoic Acids; D011758:Pyrroles; D049993:Sodium Chloride Symporter Inhibitors; D017311:Amlodipine; D001262:Atenolol; D000069059:Atorvastatin; D017292:Doxazosin; D020913:Perindopril